Safety and efficacy of JS']JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study

被引：0
|
作者：
Park, John J.
Gao, Bo
Beecroft, Claire
Wilkinson, Kate Jessica
Parsonson, Andrew
Zhang, Karl
Yan, Xiangyun
Wang, Ni
机构：
[1] Macquarie Univ, Sydney, Australia
[2] Blacktown Hosp, Sydney, Australia
[3] Hollywood Private Hosp, Perth, Australia
[4] Liverpool Hosp, Liverpool, Australia
[5] Alphamab Oncol Ltd, Suzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3038
引用
收藏
页数：1
相关论文
共 50 条
  • [11] First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT901 as monotherapy in patients with select advanced solid tumors
    Harvey, R. Donald
    Falchook, Gerald Steven
    Naqash, Abdul Rafeh
    Kim, Joseph W.
    Dowlati, Afshin
    Le Bruchec, Yvan
    Coudert, Isabelle
    Ervin-Haynes, Annette L.
    Sommerhalder, David
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [12] AVZO-021-1001: A first-in-human open-label, multicenter phase I/II dose-escalation and expansion study evaluating AVZO-021 in adult patients with advanced solid tumors
    Dowlati, A.
    Richardson, D. L.
    Lorusso, P.
    Spira, A. I.
    Bashir, B.
    Hirmand, M.
    Mehta, M.
    Patel, M. R.
    ANNALS OF ONCOLOGY, 2024, 35 : S405 - S405
  • [13] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Frederik Marmé
    Carlos Gomez-Roca
    Kristina Graudenz
    Funan Huang
    John Lettieri
    Carol Peña
    Zuzana Jirakova Trnkova
    Jan Eucker
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 727 - 737
  • [14] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Marme, Frederik
    Gomez-Roca, Carlos
    Graudenz, Kristina
    Huang, Funan
    Lettieri, John
    Pena, Carol
    Trnkova, Zuzana Jirakova
    Eucker, Jan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) : 727 - 737
  • [15] A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654 administered daily for 28 days to patients with advanced solid tumors.
    Garrido-Laguna, Ignacio
    Dillon, Patrick Michael
    Anthony, Stephen Patrick
    Janat-Amsbury, Margit
    Ashenbramer, Nissa
    Warner, Steven L.
    Mouritsen, Lars
    Wade, Mark L.
    Whatcott, Clifford
    Bearss, David
    Fu, Siqing
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [16] Phase I, open-label, dose-escalation trial investigating the safety and efficacy of oncolytic virus BI 1821736 in patients with advanced solid tumors.
    Tolcher, Anthony W.
    Victoria, Ivan
    Germann, Nathalie
    Luecke, Stephan
    Bailey, Mark
    Kordes, Maximilian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [17] Efficacy and safety of tolvaptan in patients with malignant ascites: a phase 2, multicenter, open-label, dose-escalation study
    Kudo, Toshihiro
    Murai, Yoshiyuki
    Kojima, Yoshitsugu
    Uehara, Kenji
    Satoh, Taroh
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (03) : 354 - 362
  • [18] A first-in-human, open-label, dose-escalation study of ERK1/2 inhibitor HMPL-295 in patients with advanced solid tumors
    Yu, X.
    Zhang, J.
    Liu, R.
    Deng, Y.
    Cai, Y.
    Sun, Y.
    Dang, Q.
    Hong, W.
    Song, Z.
    Guo, S.
    Gao, S.
    Su, W.
    Shi, M.
    Fan, S.
    Zhang, B.
    Pan, B.
    Ren, Y.
    Wang, J.
    Zhong, C.
    Ma, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1496 - S1497
  • [19] A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors
    Duca, Matteo
    Lim, Darren Wan-Teck
    Subbiah, Vivek
    Takahashi, Shunji
    Sarantopoulos, John
    Varga, Andrea
    D'Alessio, Joseph A.
    Abrams, Tinya
    Sheng, Qing
    Tan, Eugene Youchin
    Rosa, Maria Santos
    Gonzalez-Maffe, Juan
    Sand-Dejmek, Janna
    Fabre, Claire
    Martin, Miguel
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (04) : 625 - 634
  • [20] A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY AND TOLERABILITY STUDY OF NC762 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS
    Myint, Han
    Shah, Satish
    Gutierrez, Martin
    Zsiros, Emese
    Nelson, Megan
    Zeidan, Stephanie
    Myrthil, Nadia
    Morawski, Aaron
    Barbu, Alina
    Shaik, Jahangheer
    Zhou, Chelsea
    Kanellopoulou, Chrysi
    Copeland, Ron
    Cusumano, Zachary
    Flies, Dallas
    Langermann, Solomon
    Lorusso, Patricia
    Odunsi, Kunle
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A781 - A781
12345